Skip to main content

CombiMatrix Shares Up 6 Percent on News That EAI Will Deploy Its Flu Array

NEW YORK, May 17 (GenomeWeb News) - Shares in CombiMatrix were up 6 percent, or $.13, at $2.29 in mid-afternoon trading after the company said EAI, a subsidiary of Science Applications International Corporation, will deploy its array-based influenza screening technology.

 

As GenomeWeb News reported today, CombiMatrix said the deal "gets our technology into the field and into the hands of people and groups standing watch on US soil," said CMBX's CEO Amit Kumar.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.